AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 282 min read$BSX

Boston Scientific (BSX) Secures $135.7M Cardiovascular Contract

Boston Scientific (BSX) won a $135.7M contract to supply cardiovascular products to the U.S. military, spanning 2026-2031. The company is deemed undervalued at $44.11 per share, with a GF Value of $107.30, and has a GF Score of 80/100. Insiders show net selling, while 19 premium gurus hold BSX, with mixed activity.

Original reporting
gurufocus.com
Published Sep 28, 2026, 9:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 11:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BSX
Bullish
high confidence
Mentioned
$BSX
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$BSXBullishMed
01

Why it matters

The $135.7M contract provides a stable, defense‑backed revenue source through 2031, likely supporting earnings forecasts and valuation multiples.

02

Market read

A new multi‑year defense contract for a major med‑device firm is a material catalyst that could lift the stock and benefit the sector.

03

What to watch

Potential execution risk and future budget cuts could affect long‑term revenue from the contract.

Relevance 8/10Novelty 8/10Timing: today

Background

Boston Scientific is a leading medical‑device company with a market cap of ~$64B, serving hospitals and now expanding its government contract portfolio.

Company-level read

Ticker impact

$BSXBullishHigh confidence
Context

Boston Scientific was awarded a $135.7M five‑year IDIQ contract to supply cardiovascular procedural packages to the U.S. Army, Navy and Air Force.

Expected impact

likely upward pressure as investors price in the new defense revenue

Evidence & confidence

A sizable, newly disclosed government contract for a listed medical‑device maker is material and not previously reported.

Market effects

Sector

strengthens the healthcare equipment sector's exposure to defense spending

Regional

U.S. defense procurement boost may benefit domestic med‑device makers

Global

limited to U.S. defense and healthcare markets

Counterpoint

What could challenge this read

If insider selling continues, the contract may be already priced in, limiting upside.

Key entities

  • Company
    Boston Scientific Corp

    US‑listed medical‑device manufacturer (ticker BSX).

  • Government
    U.S. Department of Defense

    Awarded the IDIQ contract via the Defense Logistics Agency.

Read at source← All news

Related articles

SEP 28
$BSXMed

Why Oppenheimer Cut Boston Scientific’s Price Target by $20 Despite Keeping its Outperform Rating

Oppenheimer cut Boston Scientific's (BSX) price target to $65 from $85 due to a cybersecurity disruption and competitive pressures, but maintained an Outperform rating. The firm reduced fiscal 2026 and 2027 estimates, citing the impact of an eight-day cyberattack and competition in LAAC and EP markets. Boston Scientific reported $5.44 billion in Q2 revenue, up 7.5% YoY, but expects the cyberattack to materially impact Q3 and full-year 2026 results.

insidermonkey.com2 min
SEP 28
$BSXMedAI 8/10

Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy

The FDA cleared Boston Scientific's SpaceOAR Flex System, a hydrogel spacer for prostate cancer radiotherapy, via the 510(k) pathway. The clearance was based on the HYDROSPACE trial, which evaluates the device's safety and effectiveness in reducing radiation dose to the rectum. The device is intended for patients with low- to intermediate-risk prostate cancer undergoing external beam radiotherapy.

cancernetwork.com2 min
SEP 23
$BSXLow

Boston Scientific Corporation Announces Retirement of Arthur C. Butcher from Executive Vice President and Group President, Medsurg and Asia Pacific, Effective January 1, 2027

Boston Scientific Corporation announced that Arthur C. Butcher will retire as Executive Vice President and Group President, MedSurg and Asia Pacific, effective January 1, 2027. He will serve as a senior advisor until February 26, 2027. The company specializes in medical equipment and materials, with significant sales in cardiovascular, endodontic surgery, and neuromodulation products.

marketscreener.com1 min
SEP 23
$BSXLow

Boston Scientific MedSurg, Asia Pacific leader to retire

Boston Scientific (BSX) announced EVP Arthur Butcher will retire at year-end 2026, after 30 years with the company. Butcher, who oversees Asia-Pacific, China, and key business units, will stay as a senior advisor until February 2027. He joined in 1996 and held various leadership roles.

massdevice.com2 min